Canada-Based Field Trip Opens in Santa Monica, Joining a Growing Wave of Ketamine Clinics in LA

Keerthi Vedantam

Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.

Canada-Based Field Trip Opens in Santa Monica, Joining a Growing Wave of Ketamine Clinics in LA
trello-attachments.s3.amazonaws.com

By Tania Tbul's own admission, she's not "a drug person." But the memories of the sexual and physical abuse she endured starting at 12 stayed with her through a marriage, the birth of four children, a divorce and a handful of suicide attempts along the way.

And so, at the age of 45, she walked into Ketamine Clinics Los Angeles in Culver City.

"I was actually pulled out of my body and I was hugging my 12-year-old self and forgiving myself... I was actually out of my body," Tbul said about the first treatment. "After the first treatment, I felt like that gaping wound was starting to heal up. It was like closing up and it wasn't sore anymore."


The growing body of evidence that ketamine — once known as club drug "special k" — can be used to treat mental health disorders along with its increasing acceptance has caused a spring of clinics in Los Angeles ready to cash in on psychedelic mental health treatments. Ketamine Clinics Los Angeles was the first to open its doors to L.A. in 2014, and now Toronto-based psychedelic company Field Trip is establishing a presence in the city, utilizing ketamine as a vehicle for therapy.

"Cognitive behavioral therapy works, it just tends to take a long time to break down the defenses, get past the ego and get to really what's happening," said Field Trip co-founder Ronan Levy. "Psychedelic therapy just accelerates the process of breaking down those walls so you can start to do the work and the processing."

History of Ketamine

Developed in the wake of the Vietnam War, ketamine replaced phencyclidine (better known as PCP) as an anesthetic before its antidepressant properties were well-studied.

This allowed physicians like anesthesiologist Steven Mandel, who co-founded Ketamine Clinics Los Angeles in 2014, to use it for off-label purposes to treat depression and other mental health disorders.

At the same time, people were using it to get high. The Drug Enforcement Agency lists it as a Schedule 3 drug, along with low doses of codeine and testosterone.

In 2019, the FDA approved a version of ketamine called esketamine for mental health treatment. The drug is an antidepressant nasal spray. The move was a landmark for psychiatrists who were operating with an arsenal of oral drugs that stemmed from the 1950s.

"For the last 30 years, we've basically been using old old drugs," said David Olson, a professor at University of California, Davis. "And ketamine was really the first new exciting drug that worked differently than a lot of these previous drugs and that really opened up a whole bunch of new horizons."

Mandel has a brisk clientele. His Westchester clinic has administered more than 12,500 treatments, which consist of six ketamine intravenous treatments over a two- to three-week period. His patients run the gamut, from ages 18 and 80. Most come in for anxiety, post traumatic stress disorder and depression. But the treatments are also used to battle issues stemming from postpartum depression and suicidal ideation.

"Ketamine works for disorders, PTSD, and especially for suicidality — works in hours to a few days," he said. "This is the quickest, the safest and the most effective of all the agents that address major depression, bipolar depression and suicidality."

But the treatment has critics. Some argue the FDA was too eager to embrace the esketamine antidepressant, saying there wasn't enough evidence in the trials that the drug was better than a placebo. And, of course ketamine still has addictive properties.

Blue Cross Blue Shield Massachusetts is the only insurance company that covers intravenous ketamine injections. Treatments can cost thousands of dollars. Other insurance providers normally don't cover the procedure because it is not FDA approved, making it accessible only to those who can afford it.

Tbul came across ketamine while researching alternative treatments to the cocktail of medications she was put on as a child. She listened to a podcast interview in which Lamar Odom talked about using ketamine to cope with his struggles with mental health. Her daughter pointed out its reputation as a club drug, but after taking it, Tbul vehemently disagreed.

"It's completely wrong. Completely wrong," Tbul said. "It's somebody who's suffering from something they cannot erase from their mind."

Tbul's first treatment at Ketamine Clinics Los Angeles, in which she said she was able to console her teenage self, allowed her to forgive herself for the emotions that had weighed her down for years.

"After the treatment, it's like an acceptance. I'm very at peace with my own body," Tbul said.

The experience is common. Often patients say the drug allows them to confront traumatic situations from a distance, and look at situations with more objectivity and empathy.

New Drug Horizons

There are more than two hundred ketamine clinics scattered across the U.S., but Santa Monica caught the eye of Field Trip, which opened a clinic in September with the goal of collecting data from ketamine-based therapy sessions and studying the effects of psychedelic drugs, while also developing and testing its own psilocybin-based treatments.

"Because we're going to have access to so much data about what makes a difference in these therapies, we can actually take that data and make sure that when we pair the therapy with our own products, we're going to get to the best outcomes," co-founder Levy said.

The Canadian company — created in 2019 by former cannabis startup founders — is best known for its research and development into psychedelic drugs. The company rolled out an app to enhance the psychedelic experience and went public in October on Canada's stock exchange.

The clinic is outfitted with mid-century furniture, fluffed-up cushions and shaggy rugs, almost like an Architectural Digest spread came to life. In-person ketamine injections and subsequent therapy sessions at its Santa Monica center offer depression, anxiety and PTSD-related treatments for upwards of $5,000.

Ketamine Administration Room

It's a hefty price for depression treatment (insurance doesn't cover it — the ketamine injection at Field Trip is administered through the muscle, not the vein). The price covers six sessions, each involving a ketamine shot that lasts 45 minutes to an hour followed by traditional psychotherapy administered by trained therapists. The process, Levy said, is meant to make therapy sessions more productive and allow patients to get more out of each session.

"The psychiatrist's arsenal — what they use to treat these illnesses — a lot of these drugs were identified kind of by accident many, many years ago and haven't really identified anything new," Olson said.

The world looks much different now.

Alternative treatments to health problems are becoming increasingly popular, and legal bodies are working to invest in their research. Oregon became the first state to legalize psychedelic mushrooms to treat depression — though the rules and restrictions around it are still being hammered out — and the FDA is conducting clinical trials on the efficacy of psilocybin as a mental health treatment. Field Trip itself is researching and developing psilocybin-based treatments.

Meanwhile, innovation around ketamine has fallen by the wayside, in part due to the fact the patent expired in 2002. Any new drugs that could emerge from it, through financially-intensive research and development and clinical trials, would not be as profitable as new patented compounds.

"They're super, super expensive," Olson said. "Companies want to ensure they can recoup those costs associated with the development."

Even as ketamine clinics continue to pop up their development, experts said, is likely to be limited. But, the use of these once recreational drugs isn't likely to die down for people like Tbul who are willing to shell thousands of dollars every year for treatment.

"I wish it was more accessible to people who are really suffering," she said. "Because not everybody can afford how much it costs per treatment."

Lead art by Carolyn Figel.

https://twitter.com/KeerthiVedantam
keerthi@dot.la
Heaviside Raises $28M for Autonomous Precision Munitions

🔦 Spotlight

Hey Los Angeles,

For years, Southern California’s defense tech story has largely been told through satellites, rockets, drones and software. This week, another category stepped into the frame: autonomous precision munitions.

Los Angeles-based Heaviside Industries emerged from stealth with a $28M Series A led by Interlagos, with participation from Menlo Ventures, Flume Ventures, Cantos, Anorak Ventures and several individual defense and technology investors. The company, founded in 2024, is building autonomous precision munitions for U.S. and allied special operations and conventional forces.

The round will help Heaviside accelerate development, production and delivery of its multi-domain munitions platforms, including its first aerial and underwater systems. According to the company, its products are designed to operate in jammed and GPS-denied environments, where legacy systems can degrade or fail.

That detail matters. Modern warfare has been reshaped by unmanned systems, contested communications and the growing need for weapons that are not only precise, but affordable enough to be produced and deployed at scale. In other words, the defense tech race is not just about building more advanced systems. It is about building systems that can actually survive the battlefield they are designed for.

Heaviside has been operating in stealth for more than two years and says it has built a team of more than 50 engineers and operators across Los Angeles and Oslo, Norway. The company also says it already has a roster of U.S. and allied customers, with the new funding going toward expanding production and accelerating deliveries domestically and abroad.

For LA’s hard tech ecosystem, Heaviside adds to a growing defense-tech cluster that is less about splashy software and more about applied engineering. The company’s work sits at the intersection of autonomy, manufacturing and national security, where Southern California’s aerospace and robotics talent has become increasingly relevant.

Now onto this week’s LA venture deals and fund announcements.


🤝 Venture Deals

    LA Companies

    • Furientis emerged from stealth with a $5M pre-seed led by Silent Ventures, with participation from Bessemer Venture Partners, SV Angel and other investors. Founded in 2025, the defense technology startup is developing cost-effective, ship-based interceptor systems designed for scalable production, with the funding going toward initial production, expanded testing and hiring across engineering, manufacturing and operations. - learn more
    • Rogue raised a $2.5M pre-seed led by Science Inc., with participation from Uncommon VC, Simple Food Ventures and strategic investors, to accelerate its national retail and digital commerce strategy. Built by the team behind Dollar Shave Club and Liquid Death, Rogue makes high-protein chips and puffs with active probiotics, no seed oils and no artificial ingredients, and will launch in 2,800 Walmart stores nationwide in July. - learn more
    • Develo raised $14M led by Blueprint Equity, with participation from Villain Capital, Z21 Ventures and Bienville Capital, to grow its AI-native operating system for pediatric practices. The platform unifies clinical, billing and family engagement workflows beyond the traditional EMR, with the new capital going toward R&D and customer success as Develo expands across pediatric providers nationwide. - learn more
    LA Venture Funds
    • Kinship Ventures participated in Nectar Social’s $30M Series A, which was led by Menlo Ventures and its Anthology Fund, with participation from True Ventures and GV. Nectar Social is building an agentic social operating system for modern marketing, helping brands manage social intelligence, community engagement, creator workflows and conversational commerce across platforms like Meta, TikTok, LinkedIn, Reddit and X. The new funding will support engineering and applied AI hiring, deepen platform partnerships and expand Nectar Agent into more brand workflows. - learn more
    • Alexandria Venture Investments participated in CREATE Medicines’ $122M Series B, which was co-led by existing investors Newpath Partners, ARCH Venture Partners and Hatteras Venture Partners. The Cambridge-based biotech is developing in vivo CAR therapies for autoimmune disease and oncology using an mRNA-LNP platform that engineers immune cells directly inside the body, with the funding going toward advancing its CD19-targeted autoimmune program into the clinic, expanding its dual CAR CD19 x BCMA program and continuing work across its oncology pipeline. - learn more
    • Overture Ventures participated in GridCARE’s $64M Series A, which was led by Sutter Hill Ventures with backing from John Doerr, National Grid Partners, Future Energy Ventures, Emerson Collective, Stanford University and other existing investors. Redwood City-based GridCARE is building a physics-based AI platform that helps identify underused grid capacity and accelerate power delivery for AI data centers, compressing interconnection timelines from years to months. The company says it is already engaged in projects across more than a dozen markets representing more than 2 GW of new AI compute capacity. - learn more
    • Taste Tomorrow Ventures invested in Harken Sweets’ seed round, joining Selva and GRTSHT as the early-stage VC firm continues backing better-for-you snack brands. Founded by Katie Lefkowitz, Harken Sweets makes cleaner-label chocolate bars sweetened with whole-food dates instead of refined sugar or synthetic alternatives, and is already sold through retailers including Sprouts, Whole Foods, Kroger, Costco, Walmart, Albertsons and Wegmans. - learn more
    • Bonfire Ventures led Ranger AI’s $8.4M seed round, with participation from 25madison, Inovia Capital and Panache Ventures. Ranger AI is building an agentic revenue operations platform for industrial tendering, helping industrial, manufacturing and supply chain companies automate complex RFP, bid and project workflows. The company says its platform is already being used across more than 1,000 projects and can cut industrial tendering time by up to 50%. - learn more
    • Fika Ventures participated in Outmarket AI’s $17M Series A, which was led by Permanent Capital Ventures, with participation from SignalFire, TTV Capital, Dash Fund and senior insurance industry executives. Outmarket AI builds AI workflow software for insurance agencies and brokers, helping teams automate policy reviews, quote comparisons, renewals, coverage gap analysis, proposal building and other core workflows. The round brings the company’s total funding to $21.7M. - learn more
    • Wedbush Ventures participated in Secludy’s $4M seed round, which was led by Impression Ventures and also included LAUNCH, The Syndicate, Precursor Ventures, Hustle Fund, Script Capital, Mana Ventures and Chispa VC. San Francisco-based Secludy helps banks, payments firms and fintech companies safely use proprietary customer data to train and evaluate GenAI models by generating privacy-protected synthetic data, with the funding going toward hiring, go-to-market growth and expanding its platform across more enterprise AI workflows. - learn more
    • Sound Ventures led a new $17M funding round for Anomaly Insights, joined by Alumni Ventures and existing investors Link Ventures, Redesign Health and RRE Ventures. The New York-based company uses AI to help health systems analyze payer behavior, identify denials, underpayments and contract issues, and strengthen how providers engage with insurers across claims management and managed care negotiations. The new funding brings Anomaly’s total raised to $34M. - learn more
    • B Capital and UP.Partners participated in Havoc’s $100M Series A, backing the company’s push to scale its all-domain autonomous systems for defense operations. Havoc’s autonomy stack is designed to operate across air, sea and land platforms, and the new funding brings its total capital raised to nearly $200M as it expands deployment capacity, engineering and partnerships with defense manufacturers. - learn more
    • B Capital led Star Catcher’s oversubscribed $65M Series A, with the round co-led by Shield Capital and Cerberus Ventures. The Florida-based company is building what it calls the first power grid in space, using optical power beaming to deliver electricity on demand to satellites and other spacecraft, with the funding going toward orbital demonstrations, engineering and commercial expansion. The round brings Star Catcher’s total funding to $88M. - learn more
    • Interlagos participated in Cowboy Space Corporation’s $275M Series B, which was led by Index Ventures and valued the company at $2B. Formerly known as Aetherflux, the San Carlos-based company is building vertically integrated orbital infrastructure for the AI era, including low-Earth orbit satellites, purpose-built launch vehicles and in-orbit data centers designed to help meet rising demand for AI compute. - learn more

      Download the dot.LA App

      The LA Startup Taking on One of Parenting’s Most Frustrating Problems

      🔦 Spotlight

      Hello Los Angeles,

      Every parent knows the feeling of becoming an overnight expert in something they never wanted to learn.

      For families navigating developmental delays, behavioral health needs, autism, speech therapy, occupational therapy or pediatric mental health support, that learning curve can become a full-time job. Finding the right specialist is hard enough. Getting those specialists, pediatricians, insurers and families to actually coordinate with each other? That’s often where the system breaks.

      That’s the problem Los Angeles-based Village is trying to solve.

      The specialty pediatrics startup raised $9.5 million in seed funding this week, led by Upfront Ventures, with participation from Bling Capital, GTMFund and Perceptive Ventures.

      Its AI-powered platform is designed to bring families, providers, pediatricians and payers into one coordinated care system for children with developmental, behavioral and mental health needs.

      The company was born out of co-founder Brandon Terry’s personal experience navigating care for his daughter after she was diagnosed with a rare genetic condition. Like many parents, his family faced long waitlists, high out-of-pocket costs and a fragmented web of specialists who were not necessarily working from the same playbook.

      The pitch is not simply “find a provider faster.” Village wants to coordinate the entire team around a child, including occupational therapists, speech-language pathologists, behavioral therapists and pediatricians. Its AI agent, Vera, is designed to help with the administrative drag that often slows pediatric practices down: scheduling, documentation, billing and care coordination.

      The company’s raise also points to a less flashy, but deeply consequential corner of health tech: making complex care easier to navigate. In specialty pediatrics, the pain point is not always the quality of care itself. It is the space between appointments, referrals, insurance approvals and provider communication where families are often left to connect the dots themselves.

      So far, Village says it has built a network of more than 400 independent pediatric specialty providers in Southern California and has contracts with major commercial insurers including Blue Cross & Blue Shield, Cigna and UnitedHealthcare. The new funding will help the company expand across Southern California, into other parts of California and eventually into new states.

      In other words, the next wave of healthcare infrastructure may not look like one giant hospital system. It may look more like a connected network built around the people who have been holding the system together all along: families.

      And yes, in this case, it really does take a Village.

      Venture deals follow below.👇


      🤝 Venture Deals

        LA Companies

        • MOSH, the brain health nutrition brand co-founded by Maria Shriver and Patrick Schwarzenegger, raised a $13M Series A led by Main Street Advisors to expand nationally across grocery retailers and accelerate product innovation. The Los Angeles-based company plans to use the funding to grow its retail footprint, including an upcoming Target launch, while expanding its lineup of brain-focused nutrition products with new high-protein bars designed to support both cognitive and physical performance. - learn more
        • Spring Labs raised $5M to expand its AI-native compliance platform for banks and fintechs, with the funding led by BankTech Ventures and Haymaker Ventures. The Marina del Rey-based company is building AI agents that automate complaint handling, dispute resolution, and other compliance workflows, helping regulated financial institutions scale operations more efficiently while maintaining oversight and auditability. - learn more
        • FlowPrompt.ai secured a strategic seed investment from ART Fund SP, part of ChainBLX SPC, as the company expands its AI orchestration platform designed to help developers build and manage complex AI workflows through a visual interface. Alongside the investment, the companies also launched a global AI hackathon and builder program that will give selected founders access to funding opportunities, platform tools, and a live investor pitch event in Los Angeles later this summer. - learn more
        • Chance Studios raised $3.2M to build a unified platform for trading card game collectors, aiming to bring inventory management, marketplace activity, and community features into a single ecosystem. The round was co-led by Makers Fund and Hashed, with participation from Arbitrum Gaming Ventures, GAM3GIRL VC, and others, as the company looks to modernize how collectors buy, track, and interact around physical and digital TCG assets. - learn more

        LA Venture Funds
        • Rebel Fund participated in Moritz’s $9M seed round, backing the AI-native law firm as it looks to automate large portions of routine corporate legal work. The company combines software with experienced attorneys to speed up contract drafting and review, and says it has already handled more than $2 billion worth of contracts across over 100 companies since launching earlier this year. - learn more
        • Rebel Fund participated in Corvera’s $4.2M seed round, backing the AI-native supply chain platform as it automates back-office operations for consumer packaged goods brands. The Y Combinator-backed startup is building AI agents that can handle workflows like order processing, invoicing, and demand planning across fragmented enterprise systems, helping brands scale operations without significantly increasing headcount. - learn more
        • Chaac Ventures participated in Astrocade’s $5.6M funding round, backing the gaming startup as it builds a social gaming platform centered around community-created interactive experiences. The company is focused on blending gaming, streaming, and creator tools into a more collaborative entertainment platform, and plans to use the funding to expand development and grow its creator ecosystem. - learn more
        • Fusion VC participated in MSICS Pharma’s $3.6M funding round, backing the biotech company as it advances psilocybin-based treatments for PTSD, depression, and OCD. The company is developing medical-grade psychedelic compounds and plans to use the funding to expand production, accelerate clinical trials, and prepare for broader commercialization as interest in psychedelic therapies continues to grow. - learn more
        • JAM Fund participated in Fun’s $72M Series A, backing the payments infrastructure startup as it scales its platform for moving money across fintech and digital asset applications. The round was co-led by Multicoin Capital and SignalFire, and the company plans to use the funding to expand internationally, pursue acquisitions, and deepen its infrastructure stack as demand grows for faster global payment systems. - learn more

        LA Exits

        • Tapin2 was acquired by Greater Sum Ventures, joining MyVenue as part of GSV’s expanded point-of-sale technology platform for stadiums, arenas and live entertainment venues. Tapin2 provides self-service, suite catering and mobile ordering technology for high-volume sports and entertainment venues, while MyVenue offers cloud-native POS software across concessions, premium seating, retail, in-seat ordering and other venue operations. Together, the companies say their technology is used in more than 70% of MLB and NFL stadiums. Terms of the transaction were not disclosed. - learn more
        • Motiv Space Systems signed a definitive agreement to be acquired by Rocket Lab, bringing its space robotics, motion control systems and precision spacecraft mechanisms into Rocket Lab’s growing space systems business. Motiv’s technology has supported major missions including NASA’s Mars Perseverance rover and lunar rover programs, and the company will be rebranded as Rocket Lab Robotics after the deal closes, which is expected in the second quarter of 2026. - learn more
        • Robyn was acquired by Los Angeles-based Tot Squad, bringing its AI-powered doula tool into Tot Squad’s broader support platform for expecting and new moms. Robyn’s AI was trained on more than 70,000 de-identified messages between parents and doulas, and the acquisition will help Tot Squad offer free, around-the-clock pregnancy and early motherhood guidance alongside access to human experts like doulas, lactation consultants and sleep coaches. Terms of the deal were not disclosed. - learn more

          Download the dot.LA App

          Match Goes Niche With $100M Move

          🔦 Spotlight

          Hello Los Angeles,

          It’s May, and LA is about to have one of its more important weeks.

          The Milken Institute Global Conference 2026 returns to Beverly Hills next week, bringing together thousands of investors, operators, policymakers, and executives. It’s one of the few places where public markets, private capital, and tech actually overlap in the same rooms, and where you can usually get an early read on what capital is leaning into before it fully shows up in the data.

          This year, one theme is already starting to surface. Platforms are getting more specific, not more broad.

          This week’s news is a good example.

          Match Group is investing $100 million into Sniffies, a fast-growing, location-based platform built for gay, bi, trans, and queer men. It’s a notable move for a company best known for mainstream dating apps like Tinder and Hinge, and it signals a deeper push into more niche, community-driven platforms.

          Sniffies operates very differently from traditional dating apps. It’s more real-time, more map-based, and more focused on immediacy than long-term matching. In other words, it’s built around behavior, not profiles.

          And that’s what makes the investment interesting.

          For years, the dominant strategy in consumer platforms was scale, build one product that works for everyone. But what we’re seeing now is the opposite. The platforms that are gaining traction tend to be the ones that understand a specific audience deeply and build for how that group actually behaves.

          Match leaning into that shift isn’t just about expanding its portfolio. It’s a recognition that growth is coming from focus.

          And in a city like Los Angeles, that’s usually where things start.

          Below are this week’s venture deals and fund announcements across LA 👇


          🤝 Venture Deals

            LA Companies

            • Illuminant Surgical raised an $8.4M seed round to accelerate the rollout of its real-time anatomical projection platform, which aims to give surgeons enhanced visibility during procedures. The company’s “Skylight” system is designed to project internal imaging directly onto the patient, improving precision and reducing risk, and the funding will support product development and early commercialization efforts. - learn more
            • Jupid raised $840K in early funding to support its AI-native accounting platform, which is designed to automate bookkeeping, tax filing, and compliance for small businesses directly within banking platforms. The company is building what it describes as an embedded “AI accountant” that integrates with financial institutions to streamline operations for entrepreneurs, and plans to use the funding to expand partnerships and accelerate product development as demand grows for automated financial tools. - learn more
            • Lumicup raised a $4.38M Series A to expand its product line and scale manufacturing as it looks to meet growing demand for its consumer health and wellness products. The company plans to use the funding to increase production capacity, invest in new product development, and strengthen its distribution as it continues to grow its footprint in the market. - learn more
            • Counterpart raised a $50M Series C to expand its AI-driven “agentic insurance” platform, which helps small businesses manage growing legal and employment risks tied to AI adoption. The round was led by Valor Equity Partners with participation from existing investor Vy Capital, bringing the company’s total funding to $106M, and the capital will be used to launch new insurance products, expand risk management capabilities, and scale its underwriting platform. - learn more
            • Nervonik raised a $52.5M Series B to advance its next-generation peripheral nerve stimulation technology, which aims to deliver more precise, personalized treatment for chronic pain. The round was led by Amzak Health with participation from Elevage Medical Technologies, U.S. Venture Partners, Lumira Ventures, Foothill Ventures, and Shangbay Capital, and the company plans to use the funding to accelerate clinical programs and move toward commercialization. - learn more
            • LighthouseAI raised an $8M Series A to expand its AI-powered platform that helps pharmaceutical companies manage state licensing and regulatory compliance. The round was led by Boxcars Ventures with participation from TGVP and existing investors, and the company plans to use the funding to enhance product development, improve service delivery, and support continued growth as it scales across the pharma supply chain. - learn more

            LA Venture Funds
            • MANTIS Venture Capital participated in Rogo’s $75M Series C, backing the AI platform as it builds autonomous financial agents designed to streamline complex workflows for banks and investment firms. The round was led by Sequoia Capital and included a mix of major financial institutions and venture firms, signaling strong demand for AI tools that can augment decision-making across high-stakes finance. - learn more
            • M13 participated in Chord’s $7M funding round, backing the AI commerce platform as it builds a “context layer” designed to unify fragmented data, tools, and workflows for retail brands. The round was led by Equal Ventures with participation from Chingona Ventures and CEAS Investments, and the company aims to help operators move beyond dashboards toward systems that can make real-time decisions and automate actions across the business. - learn more
            • Fika Ventures participated in Lumian’s funding round, backing the startup as it launches an AI-native Amazon agency designed to automate and optimize how brands operate on the marketplace. The company is focused on replacing traditional agency workflows with AI-driven systems that can manage everything from advertising to operations in real time, reflecting a broader shift toward automation in e-commerce. - learn more
            • Riot Ventures co-led True Anomaly’s $650M Series D, backing the defense space startup as it scales spacecraft, software, and autonomous systems designed for national security missions in orbit. The round values the company at around $2.2 billion and brings total funding to over $1 billion since its 2022 founding, and the company plans to use the capital to accelerate mission deployments, expand manufacturing, and grow its workforce as demand increases for space-based defense capabilities. - learn more
            • Clocktower Technology Ventures participated in Clarasight’s $11.5M Series A, backing the AI-powered travel and expense platform as it works to unify fragmented enterprise data into a single system. The round was led by AlleyCorp with participation from several travel and fintech-focused investors, and the company plans to use the funding to expand product development and scale go-to-market efforts as demand grows for AI-driven efficiency in corporate travel. - learn more
            • Halogen Ventures and Mucker Capital participated in SkyfireAI’s $11M seed round, backing the startup as it builds an AI-native platform for coordinating autonomous, multi-drone operations. The company’s software is designed for public safety and defense use cases, helping teams deploy and manage fleets of drones with greater speed and efficiency without increasing staffing, and it plans to use the funding to accelerate product development, expand its team, and scale deployments with government and mission-critical customers as demand grows for autonomous drone systems. - learn more
            • Matter Venture Partners led OpenLight’s $50M Series A-1, with participation from Acclimate Ventures, Catapult Ventures, and existing investors, backing the photonics company as it scales its next-generation chip platform for AI infrastructure. The funding brings total capital raised to $84M and will be used to accelerate global deployment of its silicon photonics technology across data centers, telecom, and other high-bandwidth applications. - learn more
            • Alexandria Venture Investments participated in Fathom Therapeutics’ $47M Series A, backing the biotech startup as it applies quantum chemistry and AI to design next-generation small molecule drugs. The oversubscribed round was led by Sutter Hill Ventures with participation from Chemistry and other investors, and the company plans to advance its platform, which simulates protein behavior inside living cells to accelerate drug discovery. - learn more

              Download the dot.LA App

              RELATEDEDITOR'S PICKS
              Trending